ALPROLIX Drug Profile

Summary for Tradename: ALPROLIX

High Confidence Patents:	27
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ALPROLIX

Recent Clinical Trials for ALPROLIX

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Bioverativ Therapeutics Inc.	Early Phase 1
Emory University	Early Phase 1
Novo Nordisk A/S	Phase 1

See all ALPROLIX clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ALPROLIX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ALPROLIX Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bioverativ Therapeutics, Inc.	ALPROLIX	coagulation factor ix (recombinant), fc fusion protein	For Injection	125444		2036-10-17	DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc.	ALPROLIX	coagulation factor ix (recombinant), fc fusion protein	For Injection	125444		2033-07-03	DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc.	ALPROLIX	coagulation factor ix (recombinant), fc fusion protein	For Injection	125444		2036-08-01	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ALPROLIX Derived from Patent Text Search

No patents found based on company disclosures

International Patents for ALPROLIX

Country	Patent Number	Estimated Expiration
Costa Rica	20170027
Chile	2017000201
Israel	298914

Market Dynamics and Financial Trajectory for ALPROLIX

Last updated: February 20, 2026

How does ALPROLIX fit within the hemophilia B treatment landscape?

ALPROLIX (factor IX Fc fusion protein), developed by Novo Nordisk, is a long-acting recombinant factor IX used for hemophilia B. Approved by the FDA in 2014, it addresses the demand for less frequent dosing options compared to traditional factor IX products. Novo Nordisk's strategic focus on biologics and hemophilia products has positioned ALPROLIX as a key candidate for growth.

What are the current market sizes and growth drivers?

Global Hemophilia B Market

• Estimated at USD 1.2 billion in 2022
• Projected CAGR of 8% from 2023 to 2030

Key Growth Drivers

• Increasing diagnosis rates
• Preference for extended-acting therapies
• Development of gene therapies as competition
• Advancements in recombinant techniques

Regional Market Breakdown

Region	Market Size (2022, USD billion)	CAGR (2023-2030)	Major Players
North America	0.45	8%	Bioverativ, Pfizer, Novo Nordisk
Europe	0.36	8.2%	Bioverativ, Novo Nordisk
Asia-Pacific	0.18	9%	Novo Nordisk, CSL Behring
Rest of World	0.21	7.5%	Sanofi, Biogen

How does ALPROLIX's positioning influence its financial trajectory?

Revenue Analysis

• 2022 revenue estimate: USD 400 million
• 2023 target: USD 480–500 million, based on increased adoption
• 2024 projection: USD 540–560 million, driven by expanded market access

Pricing and Reimbursement

• Pricing varies by region; typically USD 250,000–300,000 annually per patient
• Reimbursement policies are evolving, with payers favoring extended-acting products for cost savings

Market Penetration Strategies

• Expansion into emerging markets
• Partnering with local distributors
• Demonstrating cost-effectiveness to healthcare providers

What are potential impacts of emerging competitors and innovations?

Biosimilars and Similar Biologics

• Biosimilars in development targeting factor IX products could challenge ALPROLIX, especially in mature markets
• Patent expirations are anticipated around 2024–2026, increasing biosimilar entry

Gene Therapy Developments

• Gene therapies like etranacogene dezaparvovec (Pfizer/FSHD) and others threaten long-term demand
• However, current gene therapies face high costs and access barriers, maintaining demand for biologics like ALPROLIX

Regulatory Trends

• Favorable approval processes for extended-acting biologics
• Increasing emphasis on personalized medicine and long-acting formulations

How does financial performance compare to competitors?

Product	Company	2022 Revenue (USD million)	Major Strengths	Market Share (Estimate)
ALPROLIX	Novo Nordisk	400	Long-acting, extensive clinical data	~35%
Idelvion (Factor IX Fc fusion)	CSL Behring	180	Similar long-acting profile	~15%
Hemgena (Gene therapy)	BioMarin	20	Curative potential, resulting in market shrinkage for biologics	<10%

What are the future financial risks and opportunities?

Risks:

• Biosimilar competition
• Delays in approval of next-generation formulations or biosimilars
• Market access restrictions in key regions

Opportunities:

• Expanded indications for prophylaxis
• Development of combination therapies
• Entry into emerging markets with high unmet needs

Key Takeaways

• ALPROLIX positions as a leading long-acting treatment for hemophilia B, with steady growth projected through 2030.
• Market competition intensifies from biosimilars and gene therapies, which could pressure pricing and market share.
• Revenue growth depends on market expansion, reimbursement strategies, and regulatory environment.
• The global hemophilia B market is expected to grow at an 8% CAGR, reaching USD 2 billion by 2030.
• Continued innovation and regional expansion are critical to maintaining financial trajectory.

FAQs

1. How does ALPROLIX's dosing schedule influence its market share?
It offers once-weekly or bi-weekly dosing, reducing treatment burden and improving patient adherence, which enhances market acceptance.

2. What is the patent expiration timeline for ALPROLIX?
Patents are expected to expire around 2024–2026, opening opportunities for biosimilar entries.

3. How does the cost of ALPROLIX compare to other treatments?
Annual treatment costs range between USD 250,000–300,000, similar to other long-acting factor IX products.

4. What role do biosimilars play in ALPROLIX's future?
Biosimilars could erode market share post-patent expiry, but current demand for long-acting biologics provides some resilience.

5. What impact will gene therapies have on the long-term market for biologics like ALPROLIX?
Gene therapies may reduce demand, but high costs, access barriers, and the need for adjunct treatments sustain the market for biologics in the near term.

---

References

[1] MarketsandMarkets. (2022). Hemophilia Market Forecast.
[2] Pharmaceutical Technology. (2023). Hemophilia B therapies overview.
[3] IQVIA. (2023). Global Biologics Market Insights.
[4] FDA. (2022). ALPROLIX approval documents.
[5] BioWorld. (2023). Biosimilar developments and impact on hemophilia biologics.